Controversies in preventive therapy for children contacts of multidrug-resistant tuberculosis

Journal of Chemotherapy

Volumn 26, Issue 1, 2014, Pages 1-12

  Chiappini, Elena ^a   Sollai, Sara ^a   Bonsignori, Francesca ^a   Galli, Luisa ^a   De Martino, Maurizio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Children; IGRA; Multidrug resistant; TB contact; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; POLYPEPTIDE; PROTIONAMIDE; RIFAMPICIN; STREPTOMYCIN; VIOMYCIN;

ANTIBIOTIC SENSITIVITY; CHEMOPROPHYLAXIS; CLINICAL EXAMINATION; FOLLOW UP; HUMAN; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; META ANALYSIS (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST;

CHILDREN,; IGRA,; MULTIDRUG-RESISTANT,; TB-CONTACT,; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CHILD; CONTACT TRACING; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 84893048186     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000105     Document Type: Review

References (48)

1. World Health Organization. Stop TB partnership childhood TB subgroup. Chapter 4: childhood contact screening and management. Int J Tuberc Lung Dis. 2007;11:12-5.
2. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 global report on surveillance and response (WHO/HTM/TB/20103). Geneva: World Health Organization; 2010.
3. WHO. Global tuberculosis report 2012. Geneva: World Health Organization; 2012.
4. Pedrazzoli D, Fulton N, Anderson L, Lalor M, Abubakar I, Zenner D. Tuberculosis in the UK: 2012 report. London: Health Protection Agency; 2012. Available from: http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1317134916916
5. Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J. 2012 Dec 20. [Epub ahead of print].
6. American Academy of Pediatrics. Tuberculosis. In:Pickering LK, (ed.) Red book: report of the committee on infectious diseases, 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 680-701.
7. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N Engl J Med. 2007;356:656-9.
8. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80.
9. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology (MOOSE) group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283:2008-12.
10. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMRW Recomm Rep. 2005;34:1-37.
11. Reichler MR, Reves R, Bur S, Thompson V, Mangura BT, Ford J, et al. Evaluation of investigation conducted to detect and prevent transmission of tuberculosis. JAMA. 2002;287: 991-5.
12. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:359-68.
13. Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, Carvalho CE, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996;153:331-5.
14. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month followup. Pediatrics. 2002;109:765-71.
15. Pineiro Perez R, Mellado Pena MJ, Mendez Echevarria A, Cilleruelo Ortega MJ, García Hortelano M, Villota Arrieta J, et al. Exposure to multiresistant tuberculosis: study and follow-up of nine children. An Pediatr (Barc). 2008;68:490-5.
16. Fred D, Desai M, Song R, Bamrah S, Pavlin BI, Heetderks A, et al. Multi-drug resistant tuberculosis in Chuuk State Federated States of Micronesia, 2008-2009. Pac Health Dialog. 2010;16:123-7.
17. Tochon M, Bosdure E, Salles M, Beloncle C, Chadelat K, Dagorne M, et al. Management of young children in contact with an adult with drug-resistant tuberculosis, France, 2004-2008. Int J Tuberc Lung Dis. 2011;15:326-30.
18. Partners in Health. PIH guide to the medical management of multidrug-resistant tuberculosis. Boston, MA: Partners in Health; 2003.
19. NICE. CG117. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence; 2011.
20. Seddon JA, Furin JJ, Gale M, Del Castillo Barrientos H, Hurtado RM, Amanullah F, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med. 2012 Sep 13. [Epub ahead of print].
21. Joint statement of the US Centers for Disease Control and Prevention, The American Thoracic Society, and the Infectious Diseases Society of America: Centers for Disease Control, Atlanta, Georgia, USA. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep. 1992;41:61-71.
22. Department of Health, Republic of South Africa. Management of drug-resistant tuberculosis: policy guidelines 2011. Pretoria: Ministry of Health; 2011.
23. Al-Dabbagh M, Lapphra K, McGloin R, Inrig K, Shaaf HS, Marais BJ, et al. Drug-resistant tuberculosis: pediatric guidelines. Pediatr Infect Dis J. 2011;30:501-5.
24. Francis J Curry National Tuberculosis Center. Drug-resistant tuberculosis: a survival guide for clinicians, 2nd ed. San Francisco, CA: Francis J Curry National Tuberculosis Center; 2008.
25. Cain KP, Nelson LJ, Cegielski JP. Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2010;14:269-74.
26. Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev. 2011;12:31-8.
27. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of children exposed to multidrugresistant Mycobacterium tuberculosis. Lancet Infect Dis. 2012;12:469-79.
28. WHO. Guidelines for the programmatic management of drugresistant tuberculosis. Available at: http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf
29. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621-9.
30. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes of children with multi-drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:449-56.
31. Shaaf HS, Shean K, Donald PR. Culture confirmed multidrugresistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child. 2003;88:1106-11.
32. Drobac PC, Mukherjee JS, Joseph JK, Mitnick C, Furin JJ, del Castillo H, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117:2022-9.
33. Méndez Echevarría A, Baquero Artigao F, García Miguel MJ, Rojo Conejo P, Ballesteros Díez Y, Rubio Gribble B, et al. Multidrug-resistant tuberculosis in the pediatric age group. An Pediatr (Barc). 2007;67:206-11.
34. Feja K, McNelley E, Tran CS, Burzynski J, Saiman L. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr Infect Dis J. 2008;27:907-12.
35. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California 1994-2003. JAMA. 2005;293:2732-9.
36. Seddon JA, Hesseling AC, Willemse M, Donald PR, Shaaf HS. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment and outcome. Clin Infect Dis. 2012;54:157-66.
37. Fairlie L, Beilis NC, Reubenson G, Moore DP, Mandhi SA. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross-sectional study. BMC Infect Dis. 2011:11:28.
38. Leimane V, Ozere I. Challenging of managing a child with MDR-TB:41st world conference on lung health of the International Union Against Tuberculosis and Lung Disease (The Union), Cancun, Mexico, 3-7 December 2009.
39. AIFA Agenzia Italiana del Farmaco. Available from: http://www.agenziafarmaco.gov.it/it/content
40. DrugsFDA: FDA approved drug products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
41. Sneag DB, Shaaf HS, Cotton MF, Zar HJ. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases. Pediatr Infect Dis J. 2007;26:1142-6.
42. World Health Organization, Geneva, Switzerland. Guidelines for the programmatic management of drug-resistant tuberculosis-emergency update. WHO/HTM/TB/2008402 2008.
43. Seddon JA, Hesseling AC, Marais BJ, McIlleron H, Peloquin CA, Donald PR, et al. Paediatric use of second-line antituberculosis agents: A review. Tuberculosis. 2012;92:9-17.
44. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis. 2003;3:432-42.
45. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003;47:653-7.
46. Rodriguez JC, Cebrian L, Lopez M, Ruiz M, Jimenez I, Royo G. Mutant prevention concentration: Comparison of fluoroquinolones and linezolid with mycobacterium tuberculosis. J Antimicrob Chemother. 2004;53:441-4.
47. John S. Bradley, Mary Anne Jackson, The Committee on Infectious Diseases from The American Academy of Pediatrics. Clinical Report. The Use of Systemic and Topical Fluoroquinolones. Pediatrics. 2011;128:1034-45.
48. Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2012;32:66-88.